Philip Morris Just Raised Its Dividend 8.8%. Can It Afford Another Increase?

The US FDA authorized 20 ZYN nicotine pouches by Swedish Match USA (PMI US) to carry a modified-risk claim, stating their use instead of cigarettes lowers the risk of several smoking-related diseases. This is the first such authorization for nicotine pouches. The decision follows a scientific review and is valid for five years with mandatory market monitoring. PMI US CEO Stacey Kennedy welcomed the decision, highlighting access to science-based information for adult nicotine consumers.

The Trump administration plans to speed up approvals for smoke-free nicotine products like vapes and nicotine pouches, easing FDA review requirements. This benefits tobacco companies such as Altria (MO), Philip Morris (PM), and British American Tobacco (BTI), which face regulatory delays. The move aims to reduce illegal products but faces opposition from health advocates concerned about youth access.

Philip Morris International (PM) stock rose 2.1% after updating its Q3 2026 EPS guidance to $2.29-$2.34, exceeding estimates. The company also raised its full-year 2026 EPS forecast to $8.35-$8.50, citing favorable currency impacts. Analysts increased price targets to $205-$225. PM's defensive profile and smoke-free products supported the stock amid broader market declines.

Philip Morris (NYSE:PM) received FDA authorization for 11 nicotine-pouch products, including higher-strength Zyn Ultra pouches. The company aims to expand its market share in the fastest-growing US nicotine category, but lower pricing and increased investment may impact profitability. The FDA cited lower harmful constituents compared to other tobacco products. PM plans to invest more in Zyn as competition intensifies, particularly against British American Tobacco's Velo brand. However, the succe

Philip Morris International (NYSE: PM) raised its full-year adjusted diluted EPS forecast to $7.28-$7.43, reflecting 10.7%-12.7% growth. CEO Jacek Olczak highlighted strong pricing power and profit growth at the Barclays Global Consumer Conference. The stock, trading at $185.07, is 16.9% overvalued relative to its GF Value™ of $158.36, with a 3.16% dividend yield and a 73% payout ratio.

Philip Morris International raised its 2026 adjusted diluted EPS guidance to $8.35–$8.50, citing strong growth in smoke-free products like IQOS and ZYN. The company is expanding in the U.S. and international markets but notes regulatory and market risks.